MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Reduces Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 998,929 shares of the biopharmaceutical company's stock after selling 57,863 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.08% of Gilead Sciences worth $92,265,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of GILD. FMR LLC increased its stake in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after buying an additional 7,157,113 shares in the last quarter. Wellington Management Group LLP increased its stake in Gilead Sciences by 3.1% during the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after buying an additional 1,058,331 shares in the last quarter. Geode Capital Management LLC increased its stake in Gilead Sciences by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock worth $2,608,337,000 after buying an additional 749,047 shares in the last quarter. Norges Bank purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $1,789,254,000. Finally, Northern Trust Corp increased its stake in Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after buying an additional 2,458,954 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the sale, the chief financial officer now owns 165,674 shares of the company's stock, valued at approximately $16,537,578.68. This represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 25,429 shares of company stock worth $2,894,445 over the last ninety days. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Trading Up 2.2%

GILD traded up $2.16 during trading hours on Friday, reaching $102.50. The company's stock had a trading volume of 6,395,303 shares, compared to its average volume of 7,677,426. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business's 50-day moving average is $105.75 and its 200-day moving average is $99.76. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The stock has a market cap of $127.50 billion, a PE ratio of 277.03, a P/E/G ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same period in the prior year, the firm earned ($1.32) earnings per share. The firm's revenue was down .3% compared to the same quarter last year. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on GILD shares. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. BMO Capital Markets boosted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Oppenheimer lowered their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.